Fidia S.p.A. (BIT:FDA)
Italy · Delayed Price · Currency is EUR | Market Cap | 1.89M |
| Revenue (ttm) | 21.13M |
| Net Income (ttm) | -2.19M |
| Shares Out | 14.90M |
| EPS (ttm) | -1.15 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 897,977 |
| Average Volume | 1,590,174 |
| Open | 0.1269 |
| Previous Close | 0.1300 |
| Day's Range | 0.1207 - 0.1299 |
| 52-Week Range | 0.1075 - 7.3000 |
| Beta | -0.03 |
| RSI | 32.10 |
| Earnings Date | Nov 14, 2025 |
About Fidia
Fidia S.p.A., together with its subsidiaries, designs, manufactures, and sells high speed milling systems, numerical controls, milling heads, and software systems. Its accessories comprise HMS, a device for measuring and compensating geometric error on continuous or indexed bi-rotary heads and roto-tilting tables; TMSC, a device to measure length and diameter of the tool, as well as to check the shape; K5 tracer, a solution to perform continuous scanning of 3D surfaces; pushbutton panels; XPower digital drives for axis and spindle movement; and... [Read more]
Financial Performance
In 2024, Fidia's revenue was 17.53 million, a decrease of -38.98% compared to the previous year's 28.74 million. Losses were -9.30 million, 611.4% more than in 2023.
Financial StatementsNews
FDA Approves Innoviva's NUZOLVENCE, First-in-Class Oral Treatment For Gonorrhea
(RTTNews) - Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (INVA), announced that the U.S. Food and Drug Administration approved NUZOLVENCE (zoliflodacin) for oral suspension, a first...
FDA Approves Milestone Pharma' CARDAMYST, First Self-Administered Treatment For PSVT
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that the U.S. Food and Drug Administration has approved its first commercial product, CARDAMYST (etripamil) nasal spray. The prescription me...
FDA Approves Johnson & Johnson's AKEEGA For BRCA2-Mutated Prostate Cancer
(RTTNews) - Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration has approved its supplemental New Drug Application (sNDA) for AKEEGA—a dual-action tablet combining niraparib a...
INVA: FDA Approves Innoviva's Nuzolvence for Gonorrhea Treatment
INVA: FDA Approves Innoviva's Nuzolvence for Gonorrhea Treatment
ABBV Stock News: Lenz Therapeutics Faces Setback with FDA Report
ABBV Stock News: Lenz Therapeutics Faces Setback with FDA Report
FDA Grants Orphan Status to Amgen's (AMGN) Blinatumomab for Leukemia Treatment
FDA Grants Orphan Status to Amgen's (AMGN) Blinatumomab for Leukemia Treatment
FDA Expands Use of Johnson & Johnson's Akeega for Prostate Cancer
FDA Expands Use of Johnson & Johnson's Akeega for Prostate Cancer
FDA Approval Boosts Johnson & Johnson's (JNJ) Prostate Cancer Treatment
FDA Approval Boosts Johnson & Johnson's (JNJ) Prostate Cancer Treatment
Maharashtra Needs 771 FDA Officials As Per Union Norms, 42 Posts Filled: FDA Minister
Nagpur: Amid concerns over Pakistan-manufactured cosmetic products infiltrating Indian markets, the Maharashtra Food and Drug Administration (FDA) is .
Healthy Returns: FDA may add its strongest safety warning to Covid vaccines. Here’s what to know
The FDA is reportedly preparing to add what's known as a "black box" warning to Covid shots by the end of the year, marking a major shift in vaccine oversight.
European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy
On Friday, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Novo Nordisk A/S’ (NYSE: NVO) higher dose of Wegovy (semaglutide 7...
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back
The U.S. Food and Drug Administration (FDA) is reportedly considering adding a boxed warning — the agency's highest-level safety alert — to Covid-19 vaccines , a move that has drawn immediate criticis...
Fake medicine scare: 11 hosps flagged, 538 shops inspected, reveals FDA min
Nagpur: The state's Food and Drug Administration minister Narhari Zirwal on Friday confirmed major irregularities in the procurement and circulation o.
ImmunityBio Moves Closer To EU Approval For Bladder Cancer Therapy
The European Medicines Agency has recommended granting a conditional marketing authorization for ImmunityBio, Inc. ‘s (NASDAQ: IBRX) Anktiva (nogapendekin alfa inbakicept) in combination with Bacillu...
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
Kymera's Eczema Drug Gets Fast Track Designation in the United States
KYMR gains momentum as the FDA grants Fast Track to KT-621 for moderate to severe atopic dermatitis, boosting the stock and advancing its Type 2 pipeline.
BioCryst Gets FDA Approval To Treat Rare Childhood Swelling Disorder With Oral Drug
The U.S. Food and Drug Administration (FDA) on Friday approved BioCryst Pharmaceuticals Inc.’s (NASDAQ: BCRX) New Drug Application (NDA) for the use of an oral pellet formulation of once-daily Orlade...
FDA Approves Acadia's DAYBUE STIX Powder For Oral Solution For Rett Syndrome
(RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) announced that the FDA has approved DAYBUE STIX for oral solution for the treatment of Rett syndrome in adult and pediatric patients two years of age and...
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea
GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.
CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution
CeriBell gains FDA clearance for its continuous delirium monitoring solution, boosting its AI-driven EEG platform and expanding its role in critical care.
Amgen (AMGN) Gains FDA Nod for Expanded Use of Uplizna in Myasthenia Gravis
Amgen (AMGN) Gains FDA Nod for Expanded Use of Uplizna in Myasthenia Gravis
FDA Weighs Rapid Review For Eli Lilly Obesity Pill As Novo Nordisk Nears Launch
FDA may expedite approval timeline for ... Full story available on Benzinga.com
BioCryst's Orladeyo Oral Pellets Win FDA Nod For HAE Patients 2 To Under 12
(RTTNews) - BioCryst Pharmaceuticals, Inc. (BCRX) announced that the FDA has approved Orladeyo oral pellets for prophylactic treatment of hereditary angioedema or HAE in pediatric patients aged 2 to u...
FDA Approves Acadia's Powder Formulation Of DAYBUE For Rett Syndrome
(RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) on Friday announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE STIX, a powder formulation of DAYBUE oral solution, for the trea...
FDA Approves New Formulation for Acadia Pharmaceuticals' (ACAD) Rett Syndrome Treatment
FDA Approves New Formulation for Acadia Pharmaceuticals' (ACAD) Rett Syndrome Treatment